129 related articles for article (PubMed ID: 35709488)
1. Microdose Induction of Buprenorphine in a Patient Using Tianeptine.
Szczesniak L; Sullivan R
J Addict Med; 2022 Nov-Dec 01; 16(6):736-738. PubMed ID: 35709488
[TBL] [Abstract][Full Text] [Related]
2. Tianeptine as an opiate replacement in a patient on methadone treatment: A case report.
Velagapudi V; Calabrese J; Sethi R
J Opioid Manag; 2024; 20(1):87-91. PubMed ID: 38533719
[TBL] [Abstract][Full Text] [Related]
3. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
5. Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine/naloxone in an outpatient setting-a case report.
Martell JP; Konakanchi JS; Sethi R
J Addict Dis; 2022; 40(3):439-443. PubMed ID: 35072589
[TBL] [Abstract][Full Text] [Related]
6. A Complex Case of Kratom Dependence, Depression, and Chronic Pain in Opioid Use Disorder: Effects of Buprenorphine in Clinical Management.
Bowe A; Kerr PL
J Psychoactive Drugs; 2020; 52(5):447-452. PubMed ID: 32546067
[TBL] [Abstract][Full Text] [Related]
7. Buprenorphine Microdosing Cross Tapers: A Time for Change.
Raheemullah A; Benhamou OM; Kuo J; Lembke A
Int J Environ Res Public Health; 2022 Dec; 19(24):. PubMed ID: 36554317
[TBL] [Abstract][Full Text] [Related]
8. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine.
Tompkins DA; Smith MT; Mintzer MZ; Campbell CM; Strain EC
J Pharmacol Exp Ther; 2014 Feb; 348(2):217-26. PubMed ID: 24227768
[TBL] [Abstract][Full Text] [Related]
9. Precipitated Opioid Withdrawal Treated With Ketamine in a Hospitalized Patient: A Case Report.
Christian NJ; Butner JL; Evarts MS; Weimer MB
J Addict Med; 2023 Jul-Aug 01; 17(4):488-490. PubMed ID: 37579118
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine Microdose Induction for the Management of Prescription Opioid Dependence.
Robbins JL; Englander H; Gregg J
J Am Board Fam Med; 2021 Feb; 34(Suppl):S141-S146. PubMed ID: 33622829
[TBL] [Abstract][Full Text] [Related]
11. The problem of pain: Additive analgesic effect of tramadol and buprenorphine in a patient with opioid use disorder.
Montalvo C; Genovese N; Renner J
Subst Abus; 2019; 40(2):136-139. PubMed ID: 30835647
[No Abstract] [Full Text] [Related]
12. Single high-dose buprenorphine for opioid craving during withdrawal.
Ahmadi J; Jahromi MS; Ghahremani D; London ED
Trials; 2018 Dec; 19(1):675. PubMed ID: 30526648
[TBL] [Abstract][Full Text] [Related]
13. Educating Nurses on the Use of the Clinical Opiate Withdrawal Scale to Improve Care of Adult Patients Undergoing Buprenorphine Induction.
Uga CO; Noe SR; Lynch SA; Summers LO
J Addict Nurs; 2020; 31(4):229-235. PubMed ID: 33264194
[TBL] [Abstract][Full Text] [Related]
14. Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report.
Szczesniak LM; Calleo VJ; Sullivan RW
Harm Reduct J; 2020 Oct; 17(1):71. PubMed ID: 33028340
[TBL] [Abstract][Full Text] [Related]
15. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting.
Cisewski DH; Santos C; Koyfman A; Long B
Am J Emerg Med; 2019 Jan; 37(1):143-150. PubMed ID: 30355476
[TBL] [Abstract][Full Text] [Related]
16. Use of Buprenorphine-Naloxone in the Treatment of Tianeptine Use Disorder.
Trowbridge P; Walley AY
J Addict Med; 2019; 13(4):331-333. PubMed ID: 30550394
[TBL] [Abstract][Full Text] [Related]
17. Comparison of behavioral treatment conditions in buprenorphine maintenance.
Ling W; Hillhouse M; Ang A; Jenkins J; Fahey J
Addiction; 2013 Oct; 108(10):1788-98. PubMed ID: 23734858
[TBL] [Abstract][Full Text] [Related]
18. Low Dose Buprenorphine Induction With Full Agonist Overlap in Hospitalized Patients With Opioid Use Disorder: A Retrospective Cohort Study.
Bhatraju EP; Klein JW; Hall AN; Chen DR; Iles-Shih M; Tsui JI; Merrill JO
J Addict Med; 2022 Jul-Aug 01; 16(4):461-465. PubMed ID: 34954743
[TBL] [Abstract][Full Text] [Related]
19. Using Extended Release Buprenorphine Injection to Discontinue Sublingual Buprenorphine: A Case Series.
Ritvo AD; Calcaterra SL; Ritvo JI
J Addict Med; 2021 May-Jun 01; 15(3):252-254. PubMed ID: 32925232
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
Webster L; Hjelmström P; Sumner M; Gunderson EW
J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
